Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma☆,☆☆,★,★★
Section snippets
Patients
Healthy, stable, nonsmoking, outpatients aged 6 to 14 years with a history of typical symptoms of asthma were enrolled (Table I). Eligibility for randomization included a pre-exercise forced expiratory volume in 1 second (at least 70% of the predicted value [after withholding short-acting, inhaled β-agonist for 6 hours]) and a 20% or greater decrease in FEV1 after a standardized treadmill exercise challenge during each of 2 prestudy (prerandomization) visits.
Patients were excluded from the
Patient Demographics
Twenty-seven patients with asthma, 20 male and 7 female, were enrolled; 25 patients completed the study and were included in the analyses (Table I). Two patients (both receiving placebo) were discontinued from the study; one patient was discontinued because of an asthma exacerbation requiring oral corticosteroid treatment, and one patient was discontinued because of a protocol deviation. Other than β-agonists, no additional asthma medications were used during the course of the study.
Efficacy
There were
Discussion
We report protection against EIB by a leukotriene receptor antagonist in 6- to 14-year-old children with asthma. Montelukast (5-mg chewable tablet) demonstrated protection against EIB at the end of a once daily dosing interval in 6- to 14-year-old children, as evidenced by a significant reduction in AAC0-60min and maximum percent fall in FEV1 and by a borderline significant decrease in the time to recovery to within 5% of pre-exercise FEV1 . Although not evaluated in this study, it is likely
References (32)
- et al.
Leukotriene E4 and granulocytic infiltration into asthmatic airways
Lancet
(1993) - et al.
Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol
Res Med
(1994) Inhibition of exercise-induced asthma by theophylline
J Allergy Clin Immunol
(1984)- et al.
Demonstration by placebo response in asthma by means of exercise testing
J Psychosom Res
(1973) - et al.
Exercise-induced asthma
Am Fam Physician
(1992) - et al.
Exercise-induced asthma
Allergy
(1978) Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report
(1995)- et al.
Leukotrienes and other products of the 5-lipoxygenase pathway
N Engl J Med
(1990) - et al.
SRS-A leukotrienes decrease the activity of human respiratory cilia
Clin Allergy
(1987) - et al.
Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro
Am Rev Respir Dis
(1982)
The mechanism of vascular leakage induced by leukotriene E4
Am J Pathol
Leukotrienes are potent constrictors of human bronchi
Nature
Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects
Thorax
The effect of inhaled leukotriene D4 in humans
Am Rev Respir Dis
Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter randomized double-blind trial
Arch Intern Med
Montelukast for chronic asthma in 6- to 14-year-old children
JAMA
Cited by (258)
Pharmacological Management of Asthma and COPD
2022, Comprehensive PharmacologyRepurposing drugs as inhaled therapies in asthma
2018, Advanced Drug Delivery ReviewsEvaluating the role of leukotriene-modifying drugs in asthma management: Are their benefits ‘losing in translation’?
2016, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :Although some studies did not observe any significant benefit of the use of antileukotrienes on asthma management, on the other hand, several studies have shown that antileukotrienes provide substantial benefits not to all but to certain groups of asthmatics. Several trials have been conducted to test the efficacy of antileukotrienes on chronic persistent asthma [43,44,46–53]. It was reported that 5-LO inhibitor, A-64077 could reduce the synthesis of LTB4, thus providing a better treatment regime in cold-air induced bronchoconstriction in asthmatics [54].
Exercise-induced bronchoconstriction update—2016
2016, Journal of Allergy and Clinical ImmunologyAsthma in Older Children: Special Considerations
2016, Pediatric Allergy: Principles and Practice: Third EditionDo children with stable asthma benefit from addition of montelukast to inhaled corticosteroids: Randomized, placebo controlled trial
2015, Pulmonary Pharmacology and Therapeutics
- ☆
From Allergy and Asthma Medical Group and Research Center, San Diego, California; International Medical Technical Consultants, Inc, Prairie Village, Kansas; ASTHMA, Inc, Seattle, Washington; and Merck & Co, Inc, Rahway, New Jersey.
- ☆☆
Conflict of Interest Statement: Supported by a grant from Merck Research Laboratories. Ha H. Nguyen, PhD, Theodore F. Reiss, MD, Beth C. Seidenberg, MD, and Barbara Knorr, MD, are employees of Merck & Co, Inc and hold stock in Merck & Co, Inc. James P. Kemp, MD, Robert J. Dockhorn, MD, and Gail G. Shapiro, MD, are, or have served as, consultants for, or received honorariums or research grants from, Merck & Co, Inc.
- ★
Reprint requests: Barbara Knorr, MD, Director, Pulmonary-Immunology, Merck Research Laboratories, Merck and Co, Inc, PO Box 2000, RY33-656, Rahway, NJ 07065.
- ★★
0022-3476/98/$5.00 + 0 9/21/92598